Litigation Details for Bayer Schering Pharma AG v. Sandoz, Inc. (S.D.N.Y. 2008)

Bayer Schering Pharma AG v. Sandoz, Inc. (S.D.N.Y. 2008)

Docket		Date Filed	2008-04-18
Court	District Court, S.D. New York	Date Terminated	2012-08-27
Cause	28:1331 Fed. Question: Other	Assigned To
Jury Demand	Plaintiff	Referred To
Patents	6,787,531
Link to Docket	External link to docket

Details for Bayer Schering Pharma AG v. Sandoz, Inc. (S.D.N.Y. 2008)

Date Filed	Document No.	Description	Snippet	Link To Document
2008-04-18				External link to document

Bayer Schering Pharma AG v. Sandoz, Inc. Litigation Summary and Patent Analysis

Last updated: August 30, 2026

Bayer Schering Pharma AG v. Sandoz, Inc., No. 1:08-cv-03710, was a Hatch-Waxman patent dispute involving Bayer’s combined oral contraceptive products Yasmin and Yaz, which contain drospirenone and ethinyl estradiol. Bayer asserted U.S. Patent No. 6,787,531 against Sandoz after Sandoz filed an abbreviated new drug application with a Paragraph IV certification. The patent covered pharmaceutical compositions using micronized drospirenone to improve dissolution and bioavailability.

The litigation was materially affected by the Federal Circuit’s 2009 decision in Bayer Schering Pharma AG v. Barr Laboratories, Inc., which held the asserted patent claims invalid for obviousness. That ruling removed the patent barrier to generic entry and substantially weakened Bayer’s position against other ANDA defendants, including Sandoz.[1]

What drug products and patents were involved in Bayer v. Sandoz?

The dispute concerned drospirenone and ethinyl estradiol oral contraceptive products marketed by Bayer.

Product	Active ingredients	Regulatory product	Commercial relevance
Yasmin	Drospirenone 3 mg; ethinyl estradiol 0.03 mg	NDA 021098	Original Bayer combined oral contraceptive
Yaz	Drospirenone 3 mg; ethinyl estradiol 0.02 mg	NDA 021676	Lower-dose formulation marketed in the U.S.
Generic target	Drospirenone and ethinyl estradiol	Sandoz ANDA	Intended generic substitute for Bayer products

The principal patent was U.S. Patent No. 6,787,531, assigned to Bayer Schering Pharma AG and related entities. The patent claimed pharmaceutical compositions containing micronized drospirenone, typically in combination with ethinyl estradiol and excipients suitable for oral administration.[2]

The asserted technology addressed drospirenone’s relatively low aqueous solubility. Micronization reduced particle size and increased the surface area available for dissolution. Bayer relied on that formulation approach to support improved dissolution and predictable oral absorption.

What did U.S. Patent No. 6,787,531 protect?

The '531 patent protected pharmaceutical compositions containing micronized drospirenone. The claims were directed principally to:

• Drospirenone in micronized form;
• A combination of drospirenone with ethinyl estradiol;
• Oral pharmaceutical dosage forms;
• Dissolution characteristics associated with the micronized active ingredient; and
• Use of the composition as a hormonal contraceptive.

The patent was a formulation patent rather than a basic composition-of-matter patent covering drospirenone itself. That distinction was commercially important. Once the formulation claims were invalidated, generic manufacturers could pursue products containing the same active ingredients without facing the asserted formulation patent.

The patent did not create permanent exclusivity for every drospirenone-containing product. Its scope depended on whether a generic formulation practiced the limitations in the asserted claims, including the micronization and dissolution limitations.

When did the Bayer drospirenone patent expire?

The '531 patent had a listed expiration date in 2020, subject to any applicable patent-term adjustment or extension. The Federal Circuit’s invalidity ruling made the nominal expiration date commercially less important because an invalid patent cannot support an injunction against an otherwise approvable generic product.[1]

Event	Date or period
Patent filing and priority activity	Late 1990s to early 2000s
U.S. Patent No. 6,787,531 issued	2004
Bayer filed Hatch-Waxman action against Sandoz	2008
Federal Circuit invalidity decision in Barr litigation	2009
Nominal patent expiration	Approximately 2020
Generic competition	Began before nominal patent expiry after invalidity ruling and regulatory approvals

Patent expiration and patent enforceability must be analyzed separately. The '531 patent had remaining nominal term when the Federal Circuit invalidated the asserted claims. The ruling therefore accelerated effective generic entry.

What was the Paragraph IV basis in Bayer v. Sandoz?

Sandoz’s ANDA included a Paragraph IV certification stating that the relevant Bayer patent was invalid, unenforceable, or would not be infringed by the proposed generic product. Bayer responded by filing the civil action under 21 U.S.C. § 355(j)(5)(B)(iii).

A Paragraph IV notice triggered the Hatch-Waxman litigation process. Filing the action generally imposed a statutory 30-month stay on FDA approval of the ANDA, unless the court resolved the case earlier or otherwise modified the stay.

The case therefore presented the standard generic-entry questions:

1. Did the Sandoz formulation infringe the asserted claims?
2. Were the claims valid under the Patent Act?
3. Could Bayer obtain an injunction preventing FDA approval or commercial launch?
4. Did the Federal Circuit’s decision in the parallel Barr litigation dispose of the central patent issue?

The invalidity ruling in Barr significantly reduced the practical value of further infringement litigation based on the same claims.

What did the Federal Circuit decide in Bayer v. Barr?

In Bayer Schering Pharma AG v. Barr Laboratories, Inc., the Federal Circuit reversed the district court’s judgment upholding the '531 patent and held the asserted claims invalid as obvious under 35 U.S.C. § 103.[1]

The Federal Circuit focused on the combination of known formulation techniques and prior-art teachings concerning drospirenone and oral contraceptive products. The court concluded that a person of ordinary skill in the art would have had reason to micronize drospirenone and combine it with ethinyl estradiol in an oral contraceptive formulation.

The ruling rejected the argument that the claimed formulation represented a nonobvious technical advance. The court treated the relevant formulation steps as predictable applications of existing pharmaceutical knowledge rather than an inventive departure from the prior art.

The decision had four commercial consequences:

• The asserted claims could not support a generic-entry injunction.
• Bayer’s Orange Book patent barrier for the covered formulation was weakened.
• Other ANDA applicants received a favorable invalidity precedent.
• The value of litigation based solely on the '531 patent declined sharply.

What was the litigation status of Bayer v. Sandoz?

Bayer filed the Sandoz case in the Southern District of New York in 2008. The case was one of multiple Hatch-Waxman proceedings involving drospirenone and ethinyl estradiol products.

The reported litigation record is best understood in the context of the Barr appeal. Because the Federal Circuit invalidated the relevant '531 claims, Bayer could not obtain sustained exclusion based on those claims against Sandoz. The invalidity determination was binding as to the patent’s legal status and undermined any remaining claim for injunctive relief directed to the same patent claims.

The core litigation outcome was therefore unfavorable to Bayer:

Issue	Outcome
Patent at issue	U.S. Patent No. 6,787,531
Litigation pathway	Hatch-Waxman Paragraph IV action
Bayer’s objective	Prevent approval or launch of Sandoz generic
Central validity issue	Obviousness
Appellate result	Asserted claims held invalid
Generic-entry barrier	Removed for the invalidated claims
Settlement-based exclusivity	No reported settlement created continuing exclusion under the invalidated claims

A patent owner may still assert separate patents against an ANDA applicant if those patents claim different formulations, methods, or manufacturing processes. The Barr decision did not automatically invalidate every patent associated with Yasmin or Yaz. It did, however, eliminate the principal patent relied on for the micronized-drospirenone formulation.

How strong was Bayer’s patent estate after the invalidity ruling?

Bayer’s patent estate was weakened substantially but was not necessarily eliminated in its entirety.

Formulation patents

The '531 patent was the central formulation patent in the litigation. Its invalidity reduced protection for the commercial combination of drospirenone and ethinyl estradiol.

Additional formulation patents could still matter if they covered:

• Alternative excipient systems;
• Specific dosage strengths;
• Extended or modified-release formulations;
• Stability improvements;
• Coated tablets;
• Packaging or storage conditions; or
• Distinct dissolution profiles.

Those rights would require separate claim-by-claim infringement analysis. A generic manufacturer could design around narrower formulation claims even if the product remained therapeutically equivalent.

Method-of-use patents

Method-of-use claims may cover contraception, treatment of premenstrual dysphoric disorder, acne, or other indications. Method patents generally create a narrower barrier than composition patents because an ANDA applicant may use a Section viii statement to carve out patented indications where permitted by FDA labeling rules.

For drospirenone products, the commercial significance of a method-of-use patent depends on:

• Whether the patented indication is included in the generic label;
• Whether the proposed label would induce infringement;
• Whether the indication can be omitted without making the product commercially unattractive; and
• Whether the patent covers the entire product or only a specific patient population or dosing regimen.

Manufacturing and process patents

Process patents may protect manufacturing steps for drospirenone, micronization, blending, granulation, compression, or coating. They are less effective as broad generic-entry barriers because the relevant manufacturing process may not be disclosed in an ANDA in a manner that permits easy infringement proof.

Process patents may still increase launch risk if:

• The generic uses the same manufacturing route;
• Discovery procedures can identify the process;
• The process is necessary to achieve the claimed product characteristics; or
• The patent holder can obtain reliable evidence through discovery.

What was the FDA and Orange Book status?

The litigation was governed by the Hatch-Waxman framework. Bayer’s listed patent created the basis for the Paragraph IV action and the statutory approval stay.

The relevant regulatory structure was:

Regulatory issue	Analysis
Reference products	Yasmin and Yaz
FDA pathway	ANDA under Section 505(j)
Certification	Paragraph IV
Litigation consequence	Patent-infringement action and 30-month stay
Patent category	Formulation and product-related protection
Biologic exclusivity	Not applicable
Biosimilar pathway	Not applicable

Drospirenone and ethinyl estradiol are small-molecule active ingredients. The dispute was therefore a generic-drug case, not a biosimilar case under the Public Health Service Act.

The invalidity judgment affected patent enforceability, not FDA’s independent determination of pharmaceutical equivalence, bioequivalence, manufacturing quality, labeling, or safety. FDA approval remained dependent on the ANDA satisfying statutory and regulatory requirements.

Which companies challenged Bayer’s Yasmin and Yaz patents?

Bayer faced several generic challenges involving drospirenone and ethinyl estradiol products. The most consequential reported proceeding was Bayer’s litigation against Barr Laboratories, whose appeal produced the Federal Circuit invalidity decision.

Sandoz was another ANDA challenger. Other generic manufacturers could benefit from the invalidity ruling even if they were not parties to the Barr appeal, subject to the procedural posture of their own cases and any separate patents or exclusivity rights.

The competitive landscape included major generic manufacturers such as:

• Barr Laboratories;
• Sandoz;
• Teva-related entities;
• Mylan-related entities; and
• Other ANDA applicants seeking approval for drospirenone and ethinyl estradiol tablets.

The invalidation of the '531 patent reduced the need for each challenger to litigate the same obviousness issue independently. Generic manufacturers still faced FDA approval requirements, commercial launch planning, possible pediatric exclusivity, and any remaining listed patents.

What generic launch risks existed after the Bayer ruling?

After invalidation of the '531 patent, the principal risks shifted from the patent’s validity to execution and residual intellectual-property exposure.

Remaining patent risk

A generic applicant needed to assess any unexpired patents covering:

• A particular strength;
• A specific indication;
• A tablet composition;
• A dosage regimen;
• A manufacturing process; or
• A product-specific dissolution or stability limitation.

Regulatory risk

FDA approval could still be delayed by:

• Deficiencies in bioequivalence data;
• Manufacturing observations;
• Labeling disputes;
• REMS or safety requirements, if applicable;
• Deficiencies in the ANDA; or
• Separate statutory exclusivity periods.

Commercial risk

Generic launch economics depended on:

• The number of approved ANDAs;
• Whether a first applicant obtained 180-day exclusivity;
• The size of the branded Yaz and Yasmin market;
• Authorized generic activity;
• Reimbursement substitution; and
• The ability to enter before full generic crowding.

The invalidity ruling improved the legal launch position but did not guarantee immediate commercial entry for every applicant.

How does this case compare with biologic patent litigation?

Bayer v. Sandoz involved a conventional small-molecule ANDA and Paragraph IV certification. It did not involve:

• A biologic license application;
• A biosimilar application under Section 351(k);
• Patent dance procedures;
• Biosimilar interchangeability;
• Biologic reference-product exclusivity; or
• Manufacturing-cell-line patent disputes.

The relevant legal risk was whether the generic tablet infringed a formulation patent and whether that patent was obvious. Biosimilar litigation generally involves more extensive composition, formulation, manufacturing, and biologic-function claims.

What licensing or settlement issues affected the case?

The reported appellate record does not identify a licensing arrangement that preserved the '531 patent’s exclusionary effect. The decisive development was the Federal Circuit’s invalidity ruling in the Barr litigation.

A settlement involving a different ANDA applicant would not restore an invalid patent’s enforceability against the market generally. Any agreement would also require scrutiny under antitrust principles, including whether it delayed generic entry without a legitimate commercial justification.

Key Takeaways

• Bayer v. Sandoz was a Hatch-Waxman dispute over generic drospirenone and ethinyl estradiol products.
• The central patent was U.S. Patent No. 6,787,531.
• The patent covered micronized drospirenone formulations associated with Yasmin and Yaz.
• Sandoz challenged the patent through a Paragraph IV certification.
• The Federal Circuit held the asserted claims invalid as obvious in the parallel Barr litigation.
• The ruling removed the principal patent barrier to generic entry before the patent’s nominal 2020 expiration.
• The case involved a small-molecule generic, not a biosimilar.
• Separate method-of-use, formulation, process, or packaging patents would require independent analysis.
• Bayer’s commercial exposure increased because generic manufacturers could rely on the invalidity ruling to pursue approval and launch.
• The practical outcome turned on patent invalidity rather than a reported settlement preserving exclusivity.

FAQs About Bayer Schering Pharma AG v. Sandoz

What was the patent number in Bayer Schering Pharma AG v. Sandoz?

The principal patent was U.S. Patent No. 6,787,531, covering pharmaceutical compositions containing micronized drospirenone, including combinations with ethinyl estradiol.

Did Bayer win the drospirenone patent litigation?

Bayer initially obtained favorable treatment in the district court proceedings involving the patent, but the Federal Circuit reversed in the Barr litigation and held the asserted claims invalid for obviousness. That ruling was unfavorable to Bayer’s effort to maintain generic-entry restrictions.

Was Yasmin protected by a composition-of-matter patent?

The patent at issue was primarily a formulation patent. It did not broadly claim drospirenone as a new chemical entity. Its protection focused on micronized drospirenone pharmaceutical compositions and related dissolution characteristics.

Did the case involve FDA 180-day generic exclusivity?

The litigation arose under the ANDA framework, where first-filer status and 180-day exclusivity could affect launch timing. The reported patent decision itself did not establish a market-wide 180-day exclusivity period for all generic applicants.

Could a generic manufacturer still face patent litigation after the '531 patent was invalidated?

Yes. Separate patents could cover specific indications, dosage regimens, formulations, manufacturing processes, or other product attributes. The Federal Circuit ruling eliminated the asserted '531 claims but did not invalidate unrelated patents automatically.

Sources

1. Bayer Schering Pharma AG v. Barr Laboratories, Inc., 575 F.3d 1341 (Fed. Cir. 2009).

2. Bayer Schering Pharma AG v. Sandoz, Inc., No. 1:08-cv-03710, U.S. District Court for the Southern District of New York.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book).

4. 21 U.S.C. § 355(j).

5. 35 U.S.C. §§ 102, 103, 271(e), 282.